DLA Piper provided counsel to Axsome Therapeutics, Inc. (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, in entering into a US$570 million term loan and revolving credit facility with funds managed by Blackstone Life Sciences and Blackstone Credit & Insurance (Blackstone). Simultaneously with the credit facility, Blackstone consummated an equity investment in Axsome,

Concurrent with the new facility, Axsome has retired its previous term loan with Hercules Capital. The improved financial terms and expected use of the new facility are expected to result in a significant reduction in interest expense.